Biotech Values

[RockRat]

TGTX; ROckRat . . . If bear case is a possibility, would you consider to sell before P3 results are out?

Subsequent to the enrollment issue, the bear case is a bit stronger than it first was, since the power is down, but it's still conjecture. I think odds of success (approvable treatment) are better than even, but whether the results will be strong enough to make a dent in the marketplace is fuzzier to me now. With the share price down here, I think the risk/reward is pretty good, so I wouldn't sell before results. But I would sell on less than marketable results. It's a small position.

Regards, RockRat